Scheduling status: Fluconazole and Sodium picosulphate
The Initial Recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) on December 15, 2009 for the scheduling of:
Fluconazole when sold in a concentration of 150 mg per oral dosage unit and indicated for the treatment of vaginal candidiasis, in package sizes containing no more than 150 mg of fluconazole – Schedule III status*
(*Pursuant to removal from Schedule F of the Food and Drug Regulations and the issuance of a Notice of Compliance by Health Canada for the non-prescription product formulation)
Oral purgatives containing sodium picosulphate 10 mg per pack (when found in preparations with magnesium oxide 3.5g and citric acid 12g) – Schedule II status
Were finalized effective January 15, 2010. Final approval of the initial recommendations was made by NAPRA’s Executive Committee, in consideration of comments received during the 30-day review period. The National Drug Schedules will be revised accordingly.
